Initial validation of the clinical significance of the NETest in Japanese gastroenteropancreatic neuroendocrine tumor patients
Endocrine Journal · 2024
DOI: 10.1507/endocrj.ej24-0090 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Endocrine Journal, 2024. Verfasst von Hao Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Te…. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Stomach Neoplasms, Intestinal Neoplasms. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
As novel biomarkers for gastroenteropancreatic neuroendocrine tumors (GEPNET) are in demand, we aimed to validate the clinical value of the NETest in Japanese patients. Between 2021 and 2023, blood and clinical data were collected from patients with GEPNET. Among 35 patients (median age: 59 [49-66] years), 27 cases originated from the pancreas and eight from the gastrointestinal tract. Of 69 samples sent to the laboratory, 56 (81.2%) underwent NETest. The diagnostic sensitivity was 97.1%. Among three patients who underwent R0 resection and four treated with peptide receptor radionuclide therapy, the changes in NETest scores closely correlated with disease progression. The NETest demonstrated high diagnostic efficacy and accurate therapeutic monitoring capabilities in a Japanese population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
- Department of Gastroenterological Surgery II, Hokkaido University Faculty of Medicine, Sapporo 060-8638, Japan.
- Department of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.
- Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan.
Zitieren
APA
Zhang, H., Tsuchikawa, T., Takeuchi, S., Hirata, K., Tanaka, K., Matsui, A., Nakanishi, Y., Asano, T., Noji, T., Nakamura, T., Takeuchi, S., Wada, M., & Hirano, S. (2024). Initial validation of the clinical significance of the NETest in Japanese gastroenteropancreatic neuroendocrine tumor patients. Endocrine Journal. https://doi.org/10.1507/endocrj.ej24-0090
Vancouver
Zhang H, Tsuchikawa T, Takeuchi S, Hirata K, Tanaka K, Matsui A, et al. Initial validation of the clinical significance of the NETest in Japanese gastroenteropancreatic neuroendocrine tumor patients. Endocrine Journal. 2024. doi:10.1507/endocrj.ej24-0090
BibTeX
@article{Zhang2024,
author = {Zhang, Hao and Tsuchikawa, Takahiro and Takeuchi, Satoshi and Hirata, Kenji and Tanaka, Kimitaka and Matsui, Aya and Nakanishi, Yoshitsugu and Asano, Toshimichi and Noji, Takehiro and Nakamura, Toru and Takeuchi, Shintaro and Wada, Masataka and Hirano, Satoshi},
title = {Initial validation of the clinical significance of the NETest in Japanese gastroenteropancreatic neuroendocrine tumor patients},
journal = {Endocrine Journal},
year = {2024},
doi = {10.1507/endocrj.ej24-0090}
}
EUVIMED